(HealthDay News) – For older women with early-stage breast cancer, treatment with trastuzumab correlates with increased rates of heart failure and cardiomyopathy, according to a study published online Nov. 14 in the Journal of the American College of Cardiology.
Jersey Chen, MD, MPH, from Yale University in New Haven, CT, and colleagues used Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2000–2007) to identify 45,537 women aged 67–94 years with early-stage breast cancer. The three-year incidence of heart failure or cardiomyopathy was assessed for groups treated with trastuzumab (with or without non-anthracycline chemotherapy); anthracycline plus trastuzumab; anthracycline (without trastuzumab and with or without non-anthracycline chemotherapy); other non-anthracycline chemotherapy; or no adjuvant chemotherapy or trastuzumab therapy. Cardiac events were identified through Medicare claims.
The researchers found that adjusted three-year incidence rates were significantly higher for patients receiving trastuzumab (32.1 per 100 patients) and anthracycline plus trastuzumab (41.9 per 100 patients) than for those receiving no adjuvant therapy (18.1 per 100 patients). There were an additional 12.1, 17.9, and 21.7 heart failure or cardiomyopathy events per 100 patients over one, two, and three years of follow-up, respectively, after addition of trastuzumab to anthracycline therapy.
“In a cohort of older female Medicare beneficiaries with breast cancer, use of trastuzumab increased by more than eight-fold from 2000–2007 among patients receiving any form of adjuvant therapy,” the authors write. “The absolute incremental risk of adding trastuzumab to anthracycline for older SEER-Medicare patients was substantially higher than that reported from clinical trials enrolling younger, healthier women.”
Several authors disclosed financial ties to the pharmaceutical industry.